{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu Z"],"funding":["Foundation of National Facility for Translational Medicine","Foundation of National Facility for Translational Medicine (Shanghai)","Postdoctoral Research Foundation of China","National Natural Science Foundation of China","Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support","Shanghai Anticancer Association Eyas Project","Shanghai Sailing Program"],"pagination":["170"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8973627"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(1)"],"pubmed_abstract":["Contrast-enhanced MR angiography (MRA) is a critical technique for vascular imaging. Nevertheless, the efficacy of MRA is often limited by the low rate of relaxation, short blood-circulation time, and metal ion-released potential long-term toxicity of clinical available Gd-based contrast agents. In this work, we report a facile and efficient strategy to achieve Gd-chelated organic nanoparticles with high relaxivity for T<sub>1</sub>-weighted MRA imaging. The Gd-chelated PEG-TCPP nanoparticles (GPT NPs) have been engineered composite structured consisting of Gd-chelated TCPP and PEG. The spherical structure of TCPP offers more chemical sites for Gd<sup>3+</sup> coordination to improve the relaxivity and avoid leakage of the Gd<sup>3+</sup> ions. The synthesized GPT NPs exhibit a high relaxation rate of 35.76 mM<sup>- 1</sup> s<sup>- 1</sup> at 3.0 T, which is higher than the rates for most reported MR contrast agents. Therefore, GPT NPs can be used for MRA with much stronger vascular signals, longer circulation time, and high-resolution arterial vascular visualization than those using clinical MR contrast agents at the same dose. This work may make the T<sub>1</sub> MRI contrast agents for high-resolution angiography possible and offer a new candidate for preclinical and clinical applications of MR vascular imaging and vascular disease diagnosis."],"journal":["Journal of nanobiotechnology"],"pubmed_title":["High relaxivity Gd<sup>3+</sup>-based organic nanoparticles for efficient magnetic resonance angiography."],"pmcid":["PMC8973627"],"funding_grant_id":["SACA-CY19A04","TMSK-2021-122","19YF1410100","21YF1411500","82102190","2020M681326","20191805"],"pubmed_authors":["Liu Z","Zhao M","Peng W","Gu Y","Fu Z","Ni D","Wang H","Gao H","Tang W"],"additional_accession":[]},"is_claimable":false,"name":"High relaxivity Gd<sup>3+</sup>-based organic nanoparticles for efficient magnetic resonance angiography.","description":"Contrast-enhanced MR angiography (MRA) is a critical technique for vascular imaging. Nevertheless, the efficacy of MRA is often limited by the low rate of relaxation, short blood-circulation time, and metal ion-released potential long-term toxicity of clinical available Gd-based contrast agents. In this work, we report a facile and efficient strategy to achieve Gd-chelated organic nanoparticles with high relaxivity for T<sub>1</sub>-weighted MRA imaging. The Gd-chelated PEG-TCPP nanoparticles (GPT NPs) have been engineered composite structured consisting of Gd-chelated TCPP and PEG. The spherical structure of TCPP offers more chemical sites for Gd<sup>3+</sup> coordination to improve the relaxivity and avoid leakage of the Gd<sup>3+</sup> ions. The synthesized GPT NPs exhibit a high relaxation rate of 35.76 mM<sup>- 1</sup> s<sup>- 1</sup> at 3.0 T, which is higher than the rates for most reported MR contrast agents. Therefore, GPT NPs can be used for MRA with much stronger vascular signals, longer circulation time, and high-resolution arterial vascular visualization than those using clinical MR contrast agents at the same dose. This work may make the T<sub>1</sub> MRI contrast agents for high-resolution angiography possible and offer a new candidate for preclinical and clinical applications of MR vascular imaging and vascular disease diagnosis.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-04T08:24:39.889Z","creation":"2025-04-04T08:24:39.889Z"},"accession":"S-EPMC8973627","cross_references":{"pubmed":["35361219"],"doi":["10.1186/s12951-022-01363-3"]}}